Amgen sues Cipla for patent infringement

Amgen has filed a complaint against Cipla for allegedly infringing a patent centring on Sensipar (cinacalcet hydrochloride), which treats an overactive thyroid.

The case, which was filed yesterday, September 30, in the US District Court for the District of Delaware, arose after Cipla filed an Abbreviated New Drug Application with the Food and Drug Administration.

According to the complaint, Cipla had sought approval to manufacture a generic version of Sensipar before the expiration of US patent number 9,375,405, belonging to Amgen.

Sensipar is a treatment for secondary hyperthyroidism in patients with chronic kidney disease.

Amgen has asked the district court to prevent Cipla from manufacturing and bringing the generic drug to market.

It has further asked to be awarded costs and expenses, including attorneys’ fees, following the case.

Amgen also filed a complaint against Micro Labs, on September 22, for allegedly infringing the same patent.